

RETRACTED ARTICLE: miR-152-3p Sensitizes Glioblastoma Cells Towards Cisplatin Via Regulation Of SOSI

This article was published in the following Dove Press journal: OncoTargets and Therapy

Meihua Wang^{1,*} Qi Wu^{2,*} Mingming Fang 10^{3,*} Wu Huang⁴ Hong Zhu⁵

¹Department of Pathology, Changzhou Tumor Hospital, Affiliated to Soochow University, Changzhou, People's Republic of China; ²Department of Histology and Embryology, Heze Medical College, Heze, People's Republic of China; ³Department of Radiotherapy, Changzhou Tumor Hospital, Affiliated to Soochow University, Changzhou, People's Republic of China; ⁴Department of Neurosurgery, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, People's Republic of China; ⁵Department of Radiation Oncology, Minhang Branch of Cancer Hospital of Fudan University, Shanghai, People's Republic of China

*These authors contributed equally this work

Background: Accumulating evidences suggest that microR (s (miRNAs)) ay key roles in mediating glioblastoma progression. Decreased expression of R-152-3p vas reported in several cancer types including glioblastoma.

Methods: The sensitivity of glioblastoma cells cisplatic vas assessed by the cell counting kit-8 assay and flow cytometry analysis. The expression of miR-12-3p was determined by RT-qPCR method. Bioinformatic analysis dual lucitouse restrict assay and Western blot were used to explore the target general manalysis. 152-3p. The association between miR-152-3p and SOS1 was confirmed in glioblastoma tissue by Pearson correlation analysis.

Results: In the current study, we discovered that verexpression of miR-152-3p increased cisplatin sensitivity while in abition of miR-152-3p decreased cisplatin sensitivity in glioblastoma cells (T98G and U87 and addition, miR-152-3p augmented cell apoptosis induced by cisplatin treatment. It was the ter predict a and validated that SOS1, a protein involved in regulating chemic to a sensitivity, and a direct target gene of miR-152-3p. SOS1 was proven to suppress the cyte oxic enterpression in glioblastoma. Transfection of recombinant SOS1 could effectively record the increased cisplatin sensitivity induced by miR-152-3p overexpression in T98G. In otherwise, overexpression of SOS1 reduced the percentage of apoptotic cells in eased by miR-152-3p mimic in the presence of cisplatin in T98G. More simple target, a signal and negative correlation between miR-152-3p levels and SOS1 levels was observed in glioblastoma tissues collected from 40 patients.

Conclusio Our study identified miR-152-3p as a chemotherapy sensitizer in glioblastoma. **Seywords:** glioblastoma, miR-152-3p, SOS1, cisplatin

Introduction

Glioblastoma is recognized as main primary tumor of central nervous system. Even with active treatment including surgery, radiotherapy, and chemotherapy, the survival time after diagnosis is approximately 1–2 years. Brain tumors are a kind of highly invasive and fatal tumor disease, the incidence is 6–7 new cases per 100,000 person-years. Glioblastoma is poorly differentiated astrocytes, which are characterized by high mitotic activity, nuclear atypia, necrosis, cellular polymorphism, vascular proliferation, and thrombosis.

Cisplatin is one of the most widely used cytotoxic drugs (particularly for bladder, ovarian and testicular carcinomas) with the best curative effect for the treatment of a variety of tumors.^{5,6} Previous researches have showed that cisplatin is one of the first-line chemotherapeutic drugs adpoted for glioblastoma.^{7,8} Cisplatin is a DNA damage agent, and its cytotoxic effect is based on the formation of platinum-DNA complex and cross-linking, which leads to cell cycle arrest and



Correspondence: Wt Huang
Department of Neurosurgery, The
Affiliated Changzhou No.2 People's
Hospital of Nanjing Medical University,
Changzhou, People's Republic of China
Email czeyhw@sina.com

Hong Zhu
Department of Radiation Oncology,
Minhang Branch of Cancer Hospital of
Fudan University, Shanghai, People's
Republic of China
Email honglei19830319@126.com

enables cells to repair damage, failed DNA reparation results in cell apoptosis through activation of signaling pathways. Despite a certain initial response rate, cisplatin treatment often fails due to the development of resistance to chemotherapy. The development of cisplatin resistance greatly limits its effectiveness in glioblastoma cancer treatment. Therefore, it is of great importance to better understand the mechanism of cisplatin resistance and find an effective combination therapy to combat cisplatin resistance. Multiple studies have showed that miRNAs are involved in regulation of drug resistance in glioblastoma, which are potential biomarkers and therapeutic targets for patients with glioblastoma. The signal of the signal of

MicroRNAs (miRNAs) are endogenously expressed short non-coding RNAs of 20-23 nucleotides, 14 which bind to target gene mRNAs' complementary sequences in the 3'-untranslated regions (UTRs), and involve in regulation of diverse biological processes, including proliferation, differentiation, and apoptosis. 15 MiRNAs' expression and activity are strictly regulated in time and space, and its aberrant expression is widely associated with the development of human diseases, including cancer. 16,17 MiRNAs have been reported to play key roles during tumorigenesis and function as oncogenes tumor suppressors. 18 miR-152 has been proven to b abnormally expressed in several diseases, including cancer, and there is increasing evidences suggesting that 152 is a tumor suppressor associated with prolif migration, and invasion of humar cand Recently, Sun et al has collected glioblaston and adjacent tissues from patients who aderwent curative resection, and reported that the expression of miR-152-3p was decreased by more man half in glioblasioma tissues and glioblastoma cells mpa d with non-tumor samples and normal cells and crexpres on of miR-152-3p induced cell poptos and will ded cell invasion. 14 In this study, we expliced the function of miR-152-3p in cisplatin sensi, of glioblastoma.

Son of sevented 1 (SOS1) is a dual diguanine nucleotide exchange factor (GEF) for Ras and Rac1, which converts inactive Ras-GDP into active Ras-GTP in many EGF (Epidermal Growth Factor)-stimulated cells. SOS1 is known to participate in EGF-dependent signaling pathways and promote cell survival and growth. Moreover, dysregulation of SOS1 has been found in the progression of numerous cancers including hematological malignancies, breast cancer, skin cancer, and glioblastoma. SOS1 has two Ras binding sites, one of which is an

allosteric site distal to the active site, and activation of SOS1 by receptor tyrosine kinase (RTK) would mediate Ras activation. ²⁵ It is widely accepted that Ras plays a critical role in cell growth related signaling pathways. ²⁶ Lv Z and Yang L examined the mRNA and protein expression levels of SOS1 in glioblastoma cell lines and found that the mRNA and protein expression levels of SOS1 were higher than those of the HA cell line. ²⁴ In SOS1 knockdown U87 glioblastoma cells, Ras, p-Raf, and p-ERK were reported to be significantly downregulated, and Lv et al reported that miR-124 was also suppress the growth of U87 cells by targeting sOS1 through MAPK pathway. ²⁴

Several studies have recorted that iRNA could regulate cell proliferation of and applicosis by argeting SOS1 in cancer cells. ^{24,27} In the present, we aimed to investigate the regulate y association between miR-152-3p and SOS1 as we'll as usir roles in a gulation of glioblastoma cisplatin sensitivity. We found that miR-152-3p could increase glioblastoma cisplatin sensitivity via SOS1.

Ma erials and Methods

Clinical Lalent Tissue Samples

An of 40 tumor tissue samples from patients with problems and the corresponding 40 non-tumor tissue amples from dead healthy volunteers were collected at changzhou No.2 People's Hospital between 2016 and 2018. There were 22 males and 18 females with age ranging from 45 to 74 years, and the average age was 60.3 years. This clinical trial followed the Helsinki Declaration. Written informed consent was acquired from all patients and this study was approved by the Ethics Committee of Changzhou No.2 People's Hospital. All tissue samples were immediately frozen in liquid nitrogen after surgery and stored in a -80°C refrigerator prior to use.

Cell Culture And Reagent

T98G and U87 human glioblastoma cell lines were purchased from American Type Culture Collection (ATCC, Rockefeller, MD) and cells were cultured in Dulbecco's modified essential medium (DMEM) (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT) and 1% penicillin-streptomycin solution (Life Technologies). Cells were cultured in a 5% CO₂ humidified incubator at 37°C. Cisplatin and

Dovepress Wang et al

temozolomide (TMZ) were bought from Sigma-Aldrich (St. Louis, MO).

Overexpression And Inhibition Of miR-152-3p

MiR-NC inhibitor, miR-152-3p inhibitor, miR-NC mimic, and miR-152-3p mimic were synthesized and purchased from GenePharma (Suzhou, China). Their sequences were as follow: miR-NC inhibitor: 5'-UCGCUUGGUGCAGGU CGGGAA-3'; miR-152-3p inhibitor: 5'-CCAAGUUCUG UCAUGCACUGA-3'; miR-NC mimic: 5'-GGAACUUAG CCACUGUGAAUU-3'; miR-152-3p mimic: 5'-UCAGU GCAUGACAGAACUUGG-3'. Approximately 2×10⁶ T98G or U87 cells were seeded in each well of 6-well plates. On the next day, 50 nM miR-NC inhibitor or miR-152-3p inhibitor or miR-NC mimic or miR-152-3p mimic was mixed with 10 µL Lipofectamine RNAiMax (Life Technologies) in 250 µL serum-free DMEM for 15 mins. The mixtures were then added into indicated well in 6-well plates. After 48 hrs, the cells were subjected to the following experiments.

RNA Extraction And Reverse Transcription-Quantitative Polymeras Chain Reaction (RT-qPCR) For miRNA And mRNA Assay

rosG and Total RNA was extracted from tissues a culture U87 cells using TRIzol reagent (Vitrogo arlsbad, CA) and cDNA synthesis was perfected using Rescript RT reagent kit (TaKaRa, Otsu, Iniga, pan) according to the Manufacturer's instruct. Real-time T-qPCR reactions were performed with SYBR Premix Ex Taq (TaKaRa) in a Bio-Rad CFX96 R. Tim CR System (Bio-rad, Hercules, CA) in triplicate with A GreenTM ast qPCR Mix (TaKaRa). The reaction condons we sown as follows: pre-denature at 95° for 30 seeds, denature at 95°C for 5 seconds followed the mealing and elongation at 60°C for 10 seconds (repeated for Sycles). The relative levels of miR-152-3p and SOS1 were normalized by U6 small nucleolar RNA and GAPDH, respectively. $2^{-\Delta\Delta Ct}$ method was used to calculate gene expression level.²⁸ The primer sequences were listed as follow: stem loop primer: 5'-CTCAACTGGTGTCGT GGAGTCGGCAATTCAGTTGAGCCAAGT-3'; miR-152-3p forward primer: 5'-TCGGCAGGTCAGTGCATGACAG AA-3'; miR-152-3p reverse primer: 5'-CTCAACTGGTGTC GTGGA-3'; U6 forward primer: 5'-GAGGGCCTATTTCC CATGATT-3'; U6 reverse primer: 5'-TAATTAGAATTAAT

TTGACT-3'; SOS1 forward primer: 5'-GAGTGAATCTG CATGTCGGTT-3'; SOS1 reverse primer: 5'-CTCTCATGT TTGGCTCCTACAC-3'; GAPDH forward primer: 5'-GGAGCGAGATCCCTCCAAAAT-3'; GAPDH reverse primer: 5'-GGCTGTTGTCATACTTCTCATGG-3'.

Cell Viability And Apoptosis Assay

Cell viability assay was performed using Cell Counting Kit-8 kit (Dojindo Laboratories, Kumamoto, Japan) according to the manufacture's instruction. Probably 2×10⁶ cells were seeded into each of 6-well plates. After transfected with 50 nM R-152-3 mimic or miR-NC mimic, miR-152-3p inhibitor, or miR-N inhibitor, and 2μg pcDNA3-SOS1 or DNA3 lasmid # 48 hrs, cells were harvested and ceded in 96-wall ate, then treated with different concertrations of cisplatin (2.5, 5, 10, 20, 40 μM) for 48 13. 10 μ. CCK-8 Jution was added into each well ained for and absorbance at 450 nm reflect cell viability. Annexin-V/Dead was measured Cell ptosis Kil nvitrogen) was used to conduct cell optosis assay according to the protocol recommended by ne manufacter's instruction. Briefly, the cells were harted and vashed in cold phosphate-buffered saline en, the cells were diluted to about 1×10^6 cells/ in 1XAnnexin-binding buffer to 100 μL per assay. 5 μL Alexa Fluor 488 annexin V and 1 μL 100 μg/mL PI working solution were added to each well of cell suspension. The cells were incubated at room temperature for 15 mins, and then 400 µL annexin-binding buffer was added. Following, we analyzed the stained cells by BD FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ).

Western Blot Analysis

SOS1 antibody (Cat No. PA5-78174, 1:1000) was obtained from Thermo Fisher Scientific (Waltham, MA), GAPDH mouse monoclonal antibody (Cat No. ab8245, 1:10000) was purchased from Abcam (Cambridge, United Kingdom). Anti-mouse (Cat No. CW0221S, 1:10000) and anti-rabbit (Cat No. CW0234S, 1:10000) secondary antibodies were bought from CWBiotech (Beijing, China). Western blotting was carried out as the following procedure. After collecting cells and washing twice with cold PBS, collected cancer cells were lysed in cold RIPA buffer (Beyotime, Shanghai, China) with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), and then incubated on ice for 30 mins. After that, lysates were centrifuged at 12,000×g with 4°C for 15 mins. Protein concentration

submit your manuscript | w 9515 OncoTargets and Therapy 2019:12 DovePress

was measured by Bicinchoninic Acid Protein Assay kit (BCA, Thermo Fisher Scientific). Equal amounts (20 μ g/well) of proteins were separated by 8% SDS-PAGE, transferred to polyvinylidene fluoride (PVDF, millipore, Billerica, MA) membranes, and immunoblotted with the respective antibodies as indicated above, blots were developed with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) and the images were obtained by ImageQuant LAS 4000 (GE Healthcare, Little Chalfont, United Kingdom).

Dual-Luciferase Reporter Gene Assay

We used TargetScan (http://www.targetscan.org/) miRNA target prediction database to predict potential target genes of miR-152-3p. We amplified SOS1 3'-UTR region from cDNA of T98G cells and inserted into the pGL3 vector (Promega Corporation, Madison, WI). Two site mutations were introduced to pGL3-SOS1 3'UTR-WT to construct mutant SOS1-3'UTR (SOS1 3'UTR-Mut) with QuikChange Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA). The T98G cells were co-transfected with the 2μg SOS1 3'UTR-WT or SOS1 3'UTR-Mut plasmid and 50 nM miR-152-3p mimic (or negative control) using LipofectamineTM 2000 reagent (Invitrogen) for 48 hrs. Luciferase activity we evaluated by using the Dual-Glo Luciferase assay system (Promega Corporation).

Statistical Analysis

as thrice. In this research, we performed all experin GraphPad Prism 5.0 software (Sa iego, CA) to analyze research data and data were esented as mean ±SD. Student's t-test was used to analy differences between two groups. Q -way OVA was used to compare differences among ree more groups, followed by 0.05 v considered to indi-Newman-Keuls rsis. 1 cate a statistically sig ficant & rence.

Results

Overexpression Of miR-152-3p Enhanced Cisplatin Sensitivity In Glioblastoma

miR-152-3p has been reported as a tumor suppressor, which is downregulated in many cancer tissues. ^{19,20,29} To explore the role of miR-152-3p in regulation of cisplatin sensitivity of glioblastoma and its underlying mechanisms, we firstly over-expressed miR-152-3p in T98G and U87 glioblastoma cancer cells, respectively, and results showed that miR-152-3p mimic

successfully overexpressed miR-152-3p in the two cancer cell lines (Figure 1A). Overexpression of miR-152-3p in T98G and U87 cells did not affect glioblastoma cell viability (Figure 1B). However, overexpressed miR-152-3p significantly enhanced the cell viability inhibition in the presence of increasing concentration of cisplatin (0, 2.5, 5, 10, 20, 40 μ M) in T98G and U87 glioblastoma cancer cells (Figure 1C and D). These findings suggested that overexpression of miR-152-3p would enhance cytotoxicity of cisplatin in glioblastoma.

Inhibition Of miR-152-3r Decreted Cisplatin Sensitivity In Coblastona

Transfection of miR-152-3r ahibitor so ificant decreased miR-152-3p levels in the cell limb (Figure A). Similarly, decreased expression of iR- 2-3p did not influence cell viability of T98*C* and U87 clls (Figure 2B). In contrast to overexpression of iR-152-3p, as ceased miR-152-3p observably attenuated the cyntoxicity of cisplatin (0, 2.5, 5, 10, 20, 40 μM on cell viability in 98G and U87 cells (Figure 2C and D), these data collectively indicated that miR-152-3p could regulate cisplatin constitution in glioblastoma.

iR-152-3p Enhanced Cisplatin-Induced

The cytotoxic effect of cisplatin was mainly through induing cell apoptosis in cancer cells. ¹⁰ Flow cytometry analysis was used to detect cell apoptosis upon miR-152-3p overexpression with or without cisplatin treatment in T98G cells. Results showed that both miR-152-3p overexpression and low concentration of cisplatin (5 μM) could induce cell apoptosis in T98G, and overexpression of miR-152-3p could dramatically enhance cisplatin-induced cell apoptosis (Figure 3A and B). Furthermore, similar results were observed in U87 cells (Figure 3C and D). In agreement with indicated results, knockdown of miR-152-3p lessened cell apoptosis rate increased by cisplatin (Figure S1A). In conclusion, miR-152-3p could intensify cell apoptosis induced by cisplatin in glioblastoma.

miR-152-3p Heightened TMZ Sensitivity Of Glioblastoma Cells

Based on above findings, we surmised that miR-152-3p had the same effect on TMZ resistance of glioblastoma cells. CCK-8 assay demonstrated that enhanced expression of miR-152-3p overtly diminished cell viability suppressed by different concentrations of TMZ (0, 25, 50, 100, 200, 400 μ M)

Dovepress Wang et al




Figure 1 Overexpressed miR-152-3p strengthened cisplation duce pell viability reduction in glioblastoma cells. (**A**) MiR-152-3p mimic significantly increased miR-152-3p expression in T98G and U87 glioblastoma cells. (**B**) MiR-22-3p mimic did not in sense cell viability of T98G and U87 glioblastoma cells. (**C**) The cell viability assay results indicated that miR-152-3p mimic dramatically enhanced sisplating and T98G cell reduction with the increasing concentration of cisplatin (0, 2.5, 5, 10, 20, 40 μM). (**D**) The cell viability assay results indicated that miR-152-3p mimic dramatically enhanced sisplating assay results indicated that miR-152-3p mimic dramatically enhanced sisplating assay results indicated that miR-152-3p mimic dramatically enhanced sisplating assay results indicated that miR-152-3p mimic dramatically enhanced sisplating assay results indicated that miR-152-3p mimic significantly increased miR-152-3p mimic significantly increased miR-152-3p expression in T98G and U87 glioblastoma cells. (**C**) The cell viability assay results indicated that miR-152-3p mimic dramatically enhanced significantly increased miR-152-3p mimic dramatical


in T98G and U87 cells (Figure 4A). It was indicated by flow cytometry analysis that overexpression of piR-152-3p fortified cell apoptosis cased by .00 µM TMZ in glioblastoma (Figure 4B). Inversely, pile cing of piR-152-3p promoted cell viability in the by TriZ are reversed cell apoptosis enhanced by TMZ (Figure 41 and D). Taken together, miR-152-3p heibitg trivial stance in glioblastoma.

miR-152-3 Negatively Regulated SOSI By Binding To Its 3'-UTR

The above results indicated that miR-152-3p could enhance the anticancer effect of cisplatin, but its mechanism was still to be clarified. According to TargetScan database, SOS1 was predicted to be a potential target gene of miR-152-3p, there was a putative binding site of miR-152-3p at the SOS1 3'-UTR (Figure 5A). Overexpression of miR-152-3p dramatically restrained SOS1 mRNA and protein expression levels in

T98G and U87 glioblastoma cells (Figure 5B-D). In contrast, decreased expression of miR-152-3p observably augmented SOS1 mRNA and protein expression in T98G and U87 glioblastoma cells (Figure 5E-G). We constructed WT or Mut of SOS1 3'-UTR luciferase reporter gene plasmids to verify the association between miR-152-3p and SOS1. The dual-luciferase reporter gene assay result showed that miR-152-3p mimic dramatically decreased the luciferase activity only in the SOS1 3'-UTR-WT co-transfection system in T98G (Figure 5H). The data suggested that miR-152-3p directly repressed SOS1 expression in glioblastoma cells. Moreover, cell viability had no significant alterations when SOS1 was knocked down (Figure S1B). However, we observed that the deleption of SOS1 strengthened the inhibitory effect of cisplatin on cell viability in glioblastoma (Figure S1C). Consistently, SOS1 inhibition facilitated cell apoptosis induced by cisplatin of glioblastoma cells (Figure S1D).

Wang et al Dovepress



cell viat Figure 2 Suppression of miR-152-3p weakened cisplatin-indu reduct in glioblastoma cells. (A) MiR-152-3p inhibitor prominently reduced miR-152-3p inhibitor not affect expression in T98G and U87 glioblastoma cells. (B) MiR-152 viability of T98G and U87 glioblastoma cells. (C) T98G cells were treated with the increasing concentration of cisplatin (0, 2.5, 5, 10, 20, 40 ded with miR-NC-inhibitor or miR-152-3p inhibitor. T98G cells treated with miRin ad 152-3p inhibitor markedly decreased cisplatin-induced ression. (D) U87 cells were pre-treated with the increasing concentration of cisplatin (0, 2.5, 5, 10, bibitor. U87 cells treated with miR-152-3p inhibitor significantly reduced cisplatin-induced cell viability 20, 40 μ M), and then treated with miR-NC-inhibit r miR-152-3p suppression. **p<0.01, ***p<0.001.


miR-152-3p Strengmened Cyto xicity Of Cisplatin Via Repression Of SOSI

To further investigate where miR-12-3p regulated cis-SOS1 expression, we platin sensitivi via egula. ocDNA SOS1 recombinant plasmids and co-transfected. vi miR-132-3p mimic into T98G cells. protein expression level of SOS1 Results proved dramatically reduce when overexpressed miR-152-3p; however, when co-transfected miR-152-3p pcDNA3-SOS1 recombinant plasmid, the protein expression of SOS1 recovered (Figure 6A and B). In cell viability and apoptosis assays, data showed that overexpression of miR-152-3p would augment cisplatin-induced cell viability reduction and cell apoptosis which was reversed after transfection of recombinant (Figure 6C-E). Considering that miR-152-3p has been justified to exert its role through targeting DMNT1 in glioblastoma, we further probed the function of miR-152-3p/DMNT1 pathway in glioblastoma. Our results revealed that overexpression of DMNT1 abolished the impact of miR-152-3p upregulation on glioblastoma cell viability and apoptosis (Figure S1E-F). In conclusion, miR-152-3p regulated cisplatin sensitivity through repression of SOS1/DMNT1 expression in glioblastoma.

miR-152-3p Levels Negatively Correlated With SOS1 mRNA Expression In Glioblastoma Tumor Tissues

To explore whether regulatory association between miR-152-3p and SOS1 also exists in cancer patient samples, 40 glioblastoma tissues and paired normal samples were collected and analyzed via RT-qPCR. It was disclosed

Dovepress Wang et al



52-3p cc m-induced cell apoptosis in glioblastoma. (A) Compared to cisplatin group, T98G cells treated with cisplatin in combination with Figure 3 Mi significantly enhance cell apoptosis percentage. (B) Analyzed data from figure A, cisplatin could significantly increase T98G cell apoptosis tably enhanced by miR-152-3p overexpression. (C) Compared to cisplatin group, U87 cells treated with cisplatin in combination percentage mic could significantly enhance cell apoptosis percentage. (D) Analyzed data from figure C, cisplatin could observably increase U87 cell apoptosis with miR-152 anti-tumor effect prominently increased by miR-152-3p overexpression. ***p<0.001. percentage, and

that miR-152-3p was weakly expressed in tumor specimens compared with normal tissues (Figure 7A). The expression of SOS1 in glioblastoma samples was higher than that in non-tumor tissues (Figure 7B). Results revealed that SOS1 mRNA expression was negatively correlated with miR-152-3p levels (Figure 7C).

Discussion

Glioblastoma is a grade IV astrocytoma defined by the world health organization (WHO) which is defined as the most aggressive glioma, and is characterized by poorly differentiated neoplastic astrocytes.³⁰ Although significant achievements have been made in the past, clinical

9519 OncoTargets and Therapy 2019:12

Wang et al Dovepress




Figure 4 MiR-152-3p heightened TMZ sensitivity of glioblastoma cells. (A) The cell viability assay illustrated that miR-152-3p mimic strengthened the TMZ-induced inhibition of cell viability. (B) The role of miR-152-3p in TMZ-induced cell apoptosis was estimated by flow cytometry. (C) miR-152-3p inhibitor could remarkably elevate the viability of glioblastoma cells treated with TMZ. (D) miR-152-3p inhibitor could significantly reduce cell apoptosis percentage of glioblastoma cells treated with TMZ. *p<0.05, **p<0.01.

Dovepress Wang et al




Figure 5 MiR-152-3p negatively regulated SOS1 and could bind to its 3'-UTR. (A) Bioinformatics database prediction of the putative binding site of miR-152-3p on 3'-UTR of SOS1. (B) Compared to miR-NC mimic, miR-152-3p mimic significantly decreased SOS1 mRNA expression in T98G and U87 glioblastoma cells. (C) Compared to miR-NC mimic, miR-152-3p mimic significantly decreased SOS1 protein expression in T98G and U87 glioblastoma cells. (D) Analyzed data from figure C, miR-152-3p prominently reduced SOS1 protein expression in T98G and U87 glioblastoma cells. (E) In comparison to miR-NC inhibitor, miR-152-3p inhibitor observably increased SOS1 mRNA expression in T98G and U87 glioblastoma cells. (F) In comparison to miR-NC inhibitor, Western blot showed that miR-152-3p inhibitor observably increased SOS1 protein expression in T98G and U87 glioblastoma cells. (G) Analyzed data from figure F, miR-152-3p prominently increased SOS1 protein expression in T98G and U87 glioblastoma cells. (H) Luciferase activity was significantly decreased when co-transfected with miR-152-3p mimic and SOS1 3'UTR-WT reporter plasmid in T98G. However, luciferase activity was unaltered when co-transfected with miR-152-3p mimic and SOS1 3'UTR-Wt reporter plasmid. **p<0.01, ***p<0.001.

Wang et al **Dove**press




Figure 6 Overexpression of miR-152-3p augmented cisplatin's anti-tumor effect via repression of SOSI. (A) Compared to miR-NC mimic, miR-152-3p mimic dramatically decreased SOSI protein expression, while SOSI overexpression could reverse the downregulated SOSI expression. (B) Analyzed data from figure A, in comparison to miR-NC mimic, miR-152-3p mimic notably reduced SOSI protein expression, but additional SOSI could reverse the downregulated SOSI expression. (C) Compared to control group, miR-152-3p mimic co-transfected with pcDNA3 plasmid significantly weaken cell viability with increasing concentration of cisplatin (0, 2.5, 5, 10, 20, 40 µM), cotransfection of recombinant SOS1 plasmid and miR-152-3p reversed miR-152-3p mimic-induced decline of cell viability in T98G cells. (D) Compared to control group, miR-152-3p mimic co-transfected with pcDNA3 plasmid significantly enhanced cisplatin (5 µM) induced cell apoptosis, but transfection of recombinant SOS1 plasmid reversed miR-152-3p mimic-induced augment of cell apoptosis in T98G cells. (E) Analyzed data from figure D, compared to control group, miR-152-3p mimic co-transfected with pcDNA3 plasmid statistical significance increased cisplatin (5 µM) induced cell apoptosis, but transfection of recombinant SOS1 plasmid statistical significance reversed miR-152-3p mimic-induced augment of cell apoptosis in T98G cells. *p<0.05, **p<0.01, ***p<0.001.

Dovepress Wang et al




Figure 7 MiR-152-3p expression negative can lated with SOS RNA expression in glioblastoma tissues. (A, B) RT-qPCR analysis was applied to explore the expression of miR-152-3p and SOS1 in clinical samples. (C) parson correlation analysis showed that SOS1 mRNA expression levels were negatively correlated with miR-152-3p expression levels in tumor tissues from 40 patients on a glioblastoma (r = -0.687). **p<0.01.

treatment of paties with coblastoma remains a major challenge.³¹ As is kh value all, chanotherapy resistance is gliot stop treatment.³² Jia et al have a major protein found that miR-7.5p could inhance temozolomide sensisistant Joblastoma cells by targeting Yin Yang 1.33 2 et al have reported that exosomal transfer of miR-151a en nces chemosensitivity to temozolomide in drug-resistant glioblastoma.³⁴ Up to now, only several studies explored the role of miRNAs in cisplatin resistance of glioblastoma. 35,36 Li et al have explored that miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma.³⁵ Yang et al have discovered that miR-29a overexpression improves sensitivity of cisplatin in CD133⁺ glioblastoma cells (T98G and U87MG)

and significantly suppresses tumor growth in CD133⁺ glioblastoma tumor-bearing mice in response to cisplatin treatment.³⁶ In this research, we creatively explored the function of miR-152-3p in cisplatin sensitivity of glioblastoma, and found that miR-152-3p could increase cisplatin-induced cytotoxicity in U87 and T98G glioblastoma cells.

Since the discovery of miR-152-3p, it has been considered as a tumor suppressor in multiple solid tumors and has been shown to be abnormally down-regulated in glioblastoma. Previous studies have shown that, miR-152-3p overexpression prevents tumor cell growth in endometrial cancer, miR-152-3p suppressed cell proliferation, migration, colony formation and invasion in non-small cell lung cancer, and miR-152-3p inhibited glioblastoma cell invasion and proliferation activities via decreasing DNA

OncoTargets and Therapy 2019:12 submit your manuscript | www.dovepress.com DovePress

Methyltransferase 1 (DNMT1) and the restoration of miR-152-3p had therapeutic significance in glioblastoma treatment. 14 Additionally, miR-152-3p contributed to ovarian cancer cisplatin resistance through direct target DNMT1.40 In this research, according to TargetScan database prediction, we found that miR-152-3p could negatively regulate SOS1 and influence glioblastoma cisplatin sensitivity. SOS1 is known to be overexpressed in various cancers and plays an important role in many cascade signaling pathways. 41 Lv et al have reported that miR-124 could regulate SOS1 to affect glioblastoma growth²⁴ Our study innovatively explored the regulatory effect of miR-152-3p on SOS1 in glioblastoma, and our results suggested that SOS1 inhibited the sensitivity of glioblastoma cells to cisplatin and miR-152-3p executed its function in cisplatin resistance of glioblastoma cells via targeting SOS1.

In conclusion, our research demonstrated that miR-152-3p negatively regulated SOS1 to increase cytotoxicity of cisplatin in glioblastoma. Our findings provided new insights on the targeted delivery of miR-152-3p to glioblastoma cells as a potential therapeutic treatment for glioblastoma.

Acknowledgements

This work is supported by Medical Scientific Program o Shanghai Health and Family Planning (201540163), Scientific Program of Jia su Pro ince (BE2018643), Scientific **Program** (CJ20180029; CE20175025), 333 Jiangsu rojects (BRA2018) Scientific Research Scientific Program of Shandong Prov. ial Department of Education(J18KA254)

Disclosure

The authors report neconflict of aterest in this work.

Reference

- Jakubowicz-Gil J, Rogner E, Wertel I, Piersiak T, Rzeski W. Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line. *Chem Biol Interact*. 2010;188(1):190–203. doi:10.1016/j.cbi.2010.07.015
- DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–123. doi:10.1056/NEJM200101113440207
- Crocetti E, Trama A, Stiller C, et al. Epidemiology of glial and nonglial brain tumours in Europe. Eur J Cancer. 2012;48(10):1532–1542. doi:10.1016/j.ejca.2011.12.013
- Grobben B, Deyn PD, Slegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 2002;310(3):257–270. doi:10.1007/s00441-002-0651-7

- Yang H, Qiong-Ni Z, Jun-Li D, et al. Emerging role of long noncoding RNAs in cisplatin resistance. *Onco Targets Ther*. 2018;11:3185–3194. doi:10.2147/OTT.S158104
- Parra E, Gutiérrez L, Ferreira J. Inhibition of basal JNK activity by small interfering RNAs enhances cisplatin sensitivity and decreases DNA repair in T98G glioblastoma cells. *Oncol Rep.* 2015;33(1):413– 418. doi:10.3892/or.2014.3570
- Liu X, Sun K, Wang H, et al. Knockdown of retinoblastoma protein may sensitize glioma cells to cisplatin through inhibition of autophagy. *Neurosci Lett.* 2016;620:137–142. doi:10.1016/j.neulet.2 016.04.001
- Roberts NB, Wadajkar AS, Winkles JA, Davila E, Kim AJ, Woodworth GF. Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma. *Oncoimmunology*. 2016; 19:5–9.
- Gajski G, Čimbora-Zovko T, Rak S, Gonak M, Laj-Vrhovac V. Antitumour action on human glioblast na A1235 cells trough cooperation of bee venom and cisplan. Cytotechnology. 2016;68 (4):1197–1205. doi:10.1007/s/1.16-015-1.02-4
- Galluzzi L, Senovilla L, V de I, et al. Mediular dechanisms of cisplatin resistance. Or igene. 20 2,31:1869 83. doi:10.1038/ onc.2011.384
- 11. Qian Z, Zhou S, Z u Z, et a dir-146b-5 suppresses glioblastoma cell resistance etemozolomic throut targeting TRAF6. *Oncol Rep.* 2017;3 294, 950. doi:10.5 or:2017.5970
- 12. Wong STS, Zhang X Zhuang JT, et al. MicroRNA-21 inhibition enhancement vitro chemic unsitivity of temozolomide-resistant glioble soma cells. *Anticancer* 28, 2012;32(7):2835–2841.
- 13. Lei Y, Liao H, Liu T, et al. MiR-296-3p regulates cell growth and liti-drug resistate of human glioblastoma by targeting ether-à-go-gc (EAG1). Eu J Cancer. 2013;49(3):710–724. doi:10.1016/j.ejca. 12.08.02
- Sun J, Than X, Zhang J, et al. Regulation of human glioma cell tosis and invasion by miR-152-3p through targeting DNMT1 and regulating NF2. MiR-152-3p regulate glioma cell apoptosis and invasion. *J Exp Clin Cancer Res.* 2017;36(1):100–113. doi:10.1186/s13046-017-0567-4
- Garofalo M, Croce CM. microRNAs: master regulators as potential therapeutics in cancer. *Annu Rev Pharmacol Toxicol*. 2011;51(1):25– 43. doi:10.1146/annurev-pharmtox-010510-100517
- Ramalho-Carvalho J, Fromm B, Henrique R, Jeronimo C. Deciphering the function of non-coding RNAs in prostate cancer. Cancer Metastasis Rev. 2016;35(2):235–262. doi:10.1007/s10555-016-9628-y
- Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. *Curr Biol*. 2014;24(16):R762–R776. doi:10.1016/j.cub.2014.06.043
- 18. Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. *N Engl J Med.* 2007;302(1):1–12.
- Ma J, Yao Y, Wang P, et al. MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4. Cancer Lett. 2014;355(1):85–95. doi:10.1016/j.canlet.2014.09.012
- Azizi M, Teimoori-Toolabi L, Arzanani MK, et al. MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther. 2014;15(4):419–427. doi:10.4161/cbt.27630
- Gureasko J, Galush WJ, Boykevisch S, et al. Membrane-dependent signal integration by the Ras activator Son of sevenless. *Nat Struct Mol Biol*. 2008;15(5):452–461. doi:10.1038/nsmb.1418
- 22. Zhao C, Du G, Skowronek K, Frohman MA, Bar-Sagi D. Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. *Nat Cell Biol.* 2007;9(6):706–712. doi:10.1038/ncb1594
- Pierre S, A S B, Coumoul X. Understanding SOS (Son of Sevenless).
 Biochem Pharmacol. 2011;82(9):1049–1056. doi:10.1016/j.bcp.201
 1.07.072

Dovepress Wang et al

- 24. Lv Z, Yang L. miR-124 inhibits the growth of glioblastoma through the downregulation of SOS1. Mol Med Rep. 2013;8(2):345-349. doi:10.3892/mmr.2013.1561
- 25. Margarit SM, Sondermann H, Hall BE, et al. Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell. 2003;112(5):685-695. doi:10.1016/ s0092-8674(03)00149-1
- 26. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science. 2001;294(5545):1299-1304. doi:10.1126/ science.1062023
- 27. Liu X, Song B, Li S, Wang N, Yang H. Identification and functional analysis of the risk microRNAs associated with cerebral low-grade glioma prognosis. Mol Med Rep. 2017;16:1173-1179. doi:10.3892/ mmr.2017.6705
- 28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408. doi:10.1006/meth.2001.1262
- 29. Ge S, Wang D, Kong Q, Gao W, Sun J. Function of miR-152 as a tumor suppressor in human breast cancer by targeting PIK3CA. Oncol Res Featuring Preclin & Clin Cancer Ther. 2017;25 (8):1363-1371. doi:10.3727/096504017X14878536973557
- 30. Trejo-Solís C, Serrano-Garcia N, Escamilla-Ramírez Á, et al. Autophagic and apoptotic pathways as targets for chemotherapy in glioblastoma. Int J Mol Sci. 2018;9:3773-3827. doi:10.3390/ ijms19123773
- 31. Staberg M, Michaelsen SR, Rasmussen RD, et al. Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. Cell Oncol. 2017;40(1):21-32. doi:10.1007/s13402-016-0301-9
- 32. Messaoudi K, Clavreul A, Lagarce F. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov Today. 2015;20(7):899-905.

- 33. Jia B, Liu W, Gu J, et al. MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. Exp Cell Res. 2018;S0014.
- 34. Zeng A, Wei Z, Yan W, et al. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Cancer Lett. 2018;436:10-21. canlet.2018.08.004
- 35. Li J, Song J, Guo F. miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma. Int J Mol Med. 2019;43:517-524. doi:10.3892/ijmm.2018.3940
- 36. Yang L, Li N, Yan Z, Li C, Zhao Z. MiR-29a-mediated CD133 expression contributes to cisplatin resistance in CD133+ glioblastoma stem cells. J Mol Neurosci. 2018;66(3):369-377. doi:10.1007/ s12031-018-1177-0
- 37. You W, Zhang X, Ji M, et al. MiR icroRNA passenger ∠-5p as gastric cancer strand special functions in huma lls. Int J Biol Sci. s.25272 2018;14(6):644–653. doi:10.715
- 38. Tsuruta T, Kozaki K, Ues A, et a niR-152 is umor suppressor cancer. Cancer R 2011;71 0):645 5472.CAN-11-036 tion in endometrial methy 0):6450 doi:10.1158/0008-
- Lei L, Y L. MicroRNA-152 targets 39. Su Y, Wang ression. FEBS Lett. 2014;588 ADAM17 suppress N doi:10.101e net.2014.04.022 (10):19
- Vang D, et al. MiR-152 and miR-185 co-contribute 40. Xiang I, Ma N alls cisplatin sensitivity by targeting DNMT1 to ovarian cancel necay. a novel e enetic therapy independent of decitabine. Oncogene. 2014;33(3):378-386.
- hanced expression of SOS1 is detected in prostate Dritschilo. cancer epith ial cells from African-American men. Int J Oncol. 1–760. 2009;35(4)



OncoTargets and Therapy

OncoTargets and Therapy 2019:12

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

Dovepress

9525 DovePress